Tucatinib is an orally bioavailable tyrosine kinase inhibitor that is approved for HER2-positive MBC [11], while the phosphoinositide-3-kinase (PI3Kα) inhibitor alpelisib is approved for HER2-negative, PIK3CA-mutated advanced breast cancer [12,13]. Here, ERBB2 is linked to breast carcinoma.